Table 1 Baseline characteristics of study population (N = 46).

From: Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer

 

Patients, No. (%)

Median age, years (range)

47 (30–65)

ECOG performance status

 

0

16 (34.8)

1

30 (65.2)

Metastatic disease

42 (91.3)

Interval from advanced disease diagnosis to enrollment, months (range)

9.2 (0.6–69.2)

Median No. of prior therapies (range)

3 (2–10)

Number of lines of prior therapies in the advanced setting

 

1

13 (28.3)

2

16 (34.8)

≥3

17 (37.0)

Median No. of prior anticancer drugs type (range)

5.5 (2–12)

Sites of diseasea

 

Chest

29 (63.0)

Liver

21 (45.7)

Lung

20 (43.5)

Bone

19 (41.3)

CNS

2 (4.3)

Pleural

2 (4.3)

Othersb

2 (4.3)

Number of metastatic sites

 

<3

23 (50.0)

≥3

23 (50.0)

Liver metastasis

 

Yes

21 (45.7)

No

25 (54.3)

Combined positive score ≥ 1

 

Yes

36 (78.3)

No

8 (17.4)

Unknown

2 (4.3)

Disease-free intervalc

 

De novod

12 (26.1)

<6 months

17 (37.0)

6≤DFI < 12 months

4 (8.7)

≥12 months

13 (28.2)

Previous use of PD-1/PD-L1 antibodies

 

Yes

8 (17.4)

No

38 (82.6)

  1. aSome patients had more than one metastasis.
  2. bOne patient had splenic metastasis by radiologic assessment, and one had adrenal metastasis.
  3. cDisease-free interval was defined as the interval from completion of chemotherapy to the record of metastasis or recurrence.
  4. dPatients with de novo diseases had received at least one standard chemotherapy regimen in the advanced setting before enrollment.
Back to article page